Blood RNA and protein biomarkers are associated with vaping and dual use, and prospective health outcomes

Andrew Gregory¹, Zhonghui Xu¹, Katherine Pratte², Seth Berman¹, Robin Lu¹, Rahul Suryadevara¹, Robert Chase¹, Jeong H. Yun^{1,3}, Aabida Saferali¹, Craig P. Hersh^{1,3}, Edwin K. Silverman^{1,3}, Russell P. Bowler⁴, Laura E. Crotty Alexander^{5,6}, Adel Boueiz^{1,3*}, Peter J. Castaldi^{1,7*}

¹Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Department of Biostatistics, National Jewish Health, Denver, CO; ³Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ⁴Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO; ⁵Division of Pulmonary, Critical Care, Physiology and Sleep Medicine, University of California San Diego (UCSD), La Jolla, CA; ⁶Pulmonary Critical Care Section, Veterans Affairs (VA) San Diego Healthcare System, La Jolla, CA; ⁷Division of General Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

* Equal contribution

Corresponding Author: Peter J. Castaldi, MD, MSc, Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, Email: <u>repjc@channing.harvard.edu</u>

Authors' email addresses: Andrew Gregory (andrew.gregory@channing.harvard.edu), Zhonghui Xu (zhonghui.xu@channing.harvard.edu). Katherine Pratte (PratteK@nihealth.org). Seth Berman (seth.berman@channing.harvard.edu), Robin Lu (robin.lu@channing.harvard.edu), Rahul Suryadevara (rahul.suryadevara@channing.harvard.edu), Robert Chase (robert.chase@channing.harvard.edu), Jeong H. Yun (jeong.vun@channing.harvard.edu), Aabida Saferali (aabida.saferali@channing.harvard.edu), Craig P. (craig.hersh@channing.harvard.edu), K. Hersh Edwin Silverman (ed.silverman@channing.harvard.edu), Russell P. Bowler (BowlerR@njhealth.org), Laura E. Crotty Alexander (lca@ucsd.edu), Adel Boueiz (adel.boueiz@channing.harvard.edu), Peter J. Castaldi (peter.castaldi@channing.harvard.edu)

Author Contributions:

Drs. Boueiz and Castaldi had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, had authority over manuscript preparation and the decision to submit the manuscript for publication.

Study concept and design: Gregory, Xu, Boueiz, Castaldi

Acquisition, analysis, or interpretation of data: All authors

Drafting of the manuscript: Gregory, Boueiz, Castaldi

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Gregory, Xu, Castaldi, Boueiz

Obtained funding: Boueiz, Castaldi, Silverman

Study supervision: All authors

All authors gave final approval of the version to be published.

Keywords: biomarkers, vaping, ENDS, e-cigarettes, smoking, genomics

Abstract

Background: Electronic nicotine delivery systems (ENDS) are driving an epidemic of vaping. Identifying biomarkers of vaping and dual use (concurrent vaping and smoking) will facilitate studies of the health effects of vaping. To identify putative biomarkers of vaping and dual use, we performed association analysis in an observational cohort of 3,892 COPDGene study participants with blood transcriptomics and/or plasma proteomics data and self-reported current vaping and smoking behavior.

Methods: Biomarkers of vaping and dual use were identified through differential expression analysis and related to prospective health events over six years of follow-up. To assess the predictive accuracy of multi-biomarker panels, we constructed predictive models for vaping and smoking categories and prospective health outcomes.

Results: We identified three transcriptomic and three proteomic associations with vaping, and 90 transcriptomic and 100 proteomic associations to dual use. Many of these vaping or dual use biomarkers were significantly associated with prospective health outcomes, such as FEV1 decline (three transcripts and 62 proteins), overall mortality (18 transcripts and 73 proteins), respiratory mortality (two transcripts and 23 proteins), respiratory exacerbations (13 proteins) and incident cardiovascular disease (24 proteins). Multimarker models showed good performance discriminating between vaping and smoking behavior and produced informative, modestly powerful predictions of future FEV1 decline, mortality, and respiratory exacerbations.

Conclusions: In summary, vaping and dual use are associated with RNA and protein blood-based biomarkers that are also associated with adverse health outcomes.

1 Introduction

2 The high prevalence of electronic cigarette use (vaping) among both adolescents[1] and 3 adult cigarette users[2] is a major public health concern. Electronic cigarettes, also referred to as 4 electronic nicotine delivery systems (ENDS), were initially marketed as a means of smoking 5 reduction, with the hope that their effects on the health of cigarette users would be a net positive. 6 However, vaping is associated with acute respiratory symptoms [3–5] and lung injury [6,7] and is 7 likely to be associated with long-term adverse health effects. Vaping companies are targeting 8 young people as a profitable demographic and promoting ENDS use beyond the population of 9 established cigarette users, resulting in an ongoing epidemic of vaping in adolescents and non-10 cigarette user adults that is clearly detrimental to public health[8–10].

11 The Family Smoking Prevention and Tobacco Control Act of 2009 gave the Food and 12 Drug Administration (FDA) regulatory oversight over tobacco products which, by the FDA 13 Deeming Regulation of 2016, includes ENDS. Thus, the FDA is responsible for reviewing the 14 safety of all ENDS products introduced to market after February 15, 2007. To facilitate this 15 review process, it is important to determine whether there are validated biomarkers of ENDS use 16 and combined use of ENDS and cigarettes (dual use). While biomarkers of vaping and dual use 17 have been reported, few if any vaping biomarkers have been assessed for their association to 18 prospective health outcomes, and the predictive performance of multi-biomarker panels has not 19 been assessed. In this paper, the term biomarker refers to molecular measurements tested for 20 association to vaping or smoking exposure, which we distinguish from validated biomarkers in 21 which a specific association has been demonstrated in multiple studies. Validated biomarkers 22 that are also predictive of prospective health events can be considered for use as surrogate 23 outcomes in safety and health assessments [11,12] which would be a useful tool for evaluating

the health effects of an increasingly diverse array of ENDS products. Thus, the goal of this study
is to establish a set of candidate biomarkers for future validation and further study as potential
surrogate outcomes.

27 We hypothesized that vaping and dual use are associated to multi-omic biomarkers, and 28 that a subset of these biomarkers would be associated with the development of pulmonary and 29 cardiovascular disease. We conducted high throughput transcriptomic and proteomic analyses 30 that identified over 100 biomarkers associated with vaping and dual use in a cohort of adult 31 current and former cigarette users in the COPDGene study. We tested these biomarkers for 32 association with prospective spirometric changes, mortality, and incident cardiovascular disease, 33 identifying dozens of significantly associated biomarkers. We also investigated the extent to 34 which multimarker panels can predict vaping and smoking status and the development of 35 prospective health outcomes.

36

37 Methods

38 Study description

The COPDGene study recruited 10,198 non-Hispanic White and Black cigarette users with at least 10 pack-years of lifetime cigarette smoking history at 21 U.S. clinical centers (NCT00608764, <u>www.copdgene.org</u>)[13] between 2007 and 2011. COPDGene obtained fiveyear follow-up and is currently obtaining 10-year follow-up of available subjects to collect longitudinal data on study participants. A total of 6,756 subjects completed their five-year study visit (Visit 2) and the 10-year study visit (Visit 3) is ongoing at time of writing. Data collected includes questionnaires, spirometry, and self-reported smoking and vaping behaviors. At Visit 2,

46 whole-blood RNA sequencing (RNA-seq), plasma protein measurements (SOMAscan version 47 4.0 (5.0K) assay for human plasma), and plasma cotinine were obtained from a subset of 48 subjects. Throughout the study, subjects were also regularly contacted via the phone or Internet 49 as part of the COPDGene Longitudinal Follow-up (LFU) program to assess interval events, 50 including respiratory exacerbations, incident comorbidities, and mortality. Definitions of 51 respiratory exacerbations, incident comorbidities, and mortality assessment are included in the 52 supplementary materials of the online preprint. Written informed consents were obtained for all 53 subjects, and each clinical site obtained institutional review board approval.

54

55 Vaping and smoking groups

56 Starting from Visit 2, vaping was determined by self-report including ever use, current 57 use, intensity, cartridge size, brand, and flavoring. The four comparison groups for biomarker 58 discovery (vapers, current cigarette users, former cigarette users, and dual users) were defined 59 based on the subjects' questionnaire responses at Visit 2. Vapers were subjects who reported 60 using at least one e-cigarette within the prior week and had a history of smoking tobacco 61 cigarettes, but not within the last 30 days. Current cigarette users reported current smoking with 62 an average of at least one cigarette per day without any e-cigarette use. Dual users were vapers 63 who also reported current smoking, and former cigarette users were defined as those who 64 reported a history of smoking but did not meet criteria for current smoking or vaping. In most of 65 the reported analyses, former cigarette users are used as the reference group. Differences in 66 baseline characteristics between groups were assessed with Kruskal-Wallis and chi-square tests 67 for continuous and categorical measurements, respectively.

68

69 RNA-sequencing

70 The extraction protocol for total blood RNA was performed either manually or with the 71 Qiagen QIAcube extraction robot according to the company's standard operating procedure. 72 RNA samples with an RNA integrity number (RIN) > 6 and a concentration of $\ge 25 \ \mu g/\mu l$ were 73 sequenced. Library preparation was performed with the Illumina TruSeq Stranded Total RNA 74 with Ribo-Zero Globin kit (Illumina, Inc., San Diego, CA). Samples were sequenced to an 75 average depth of 20 million 75 base pairs (bp) paired end reads on Ilumina HiSeq 2500 76 sequencers. Samples were sequenced to an average depth of 20 million 75 base pairs (bp) paired 77 end reads on Ilumina HiSeq 2500 sequencers. Reads were aligned to the GRCh38 genome using 78 the STAR (version 2.5.2b) align. Gene annotations and transcript GTF were downloaded from 79 the Biomart Ensembl database (Ensembl Genes release 94, GRCh38.p12 assembly). Quality 80 control was performed using the FastOC and RNA-SeOC programs, and samples were included 81 for analysis if they met the following criteria: > 10 million total reads, > 80% of reads mapped to 82 the reference genome, XIST and Y chromosome expression was consistent with reported sex, < 83 10% of R1 reads in the sense orientation, Pearson correlation ≥ 0.9 with samples in the same 84 library construction batch, and concordant genotype calls between variants called from RNA 85 sequencing reads and DNA genotyping. Sequencing read counts were obtained from the 86 featureCounts function in the Rsubread R package (v1.32.2). Genes were filtered to remove very 87 low expressed genes; we limited our analysis to include only those genes which had an average 88 counts per million (CPM) value > 1 in more than 20 subjects. The trimmed mean of M values 89 (TMM) procedure from the edgeR R package (v3.24.3) was applied to account for the

90	differences in sequencing depth. The gene count data used for this analysis is available in GEO
91	(accession number GSE158699). Counts were transformed to log2 counts per million (CPM)
92	values and quantile-normalized.

93

94

4 Measurement of plasma protein biomarkers

At Visit 2, plasma samples were assayed for 4,979 proteins in 5,670 COPDGene participants using the SOMAscan Human Plasma 5.0K assay, a multiplex aptamer-based assay (SomaLogic, Boulder, Colorado)[14]. The standardization process included within-plate hybridization, median signal normalization, and plate scaling and calibration of SOMAmers to control for inter-assay variation between analytes and batch differences between plates. Inverse normal transformation was applied to all protein measurements prior to association analysis.

101

102 Cotinine measurements

103 Plasma metabolite measurements were obtained from plasma for 1,136 subjects at 104 COPDGene Visit 2 using the Metabolon Global Metabolomics Platform (Durham, NC, 105 USA)[15]. Metabolite levels were quantified as raw area counts. Plasma cotinine levels were 106 evaluated, and missing values were assigned a level of half the lowest detected amount of 107 cotinine. Values were log-transformed, and differences in cotinine distribution between groups 108 were evaluated with the Wilcoxon Rank Sum test. COPDGene metabolomic data are available in 109 the Metabolomics Workbench of the NIH Common Fund's National Metabolomics Data 110 Repository (Study ID ST001443;).

111

112 **RNA-seq differential expression and protein association analyses**

113 We used the limma R package (v3.38.3)[16] to test for the associations between RNA 114 transcripts and the vaping/smoking groups, using the former cigarette user group as the reference 115 and adjusting for age, sex, race, and library preparation batch effects. The voom function was 116 used in the RNA-seq analysis. Regression models for protein expression used identical 117 covariates, with the exception that library preparation batch effects were replaced with a variable 118 for clinical center. For both differential gene expression and protein association analyses, we 119 corrected for multiple testing with the Benjamini-Hochberg method and applied a threshold of 120 significance of a false discovery rate (FDR) of 10%[17]. For selected genes and proteins that 121 were associated in only one contrast (vaping or dual only associations), we also conducted 122 association analyses for the contrasts of vapers versus cigarette users, vapers versus dual users, 123 and dual users versus cigarette users. Gene set enrichment analysis were performed using the fast 124 gene set enrichment analysis (FGSEA) R package (v3.12)[18]. Further details are included in the 125 supplementary materials of the online preprint.

126

127 Associations of transcripts and proteins to health outcomes

Biomarkers significantly associated with vaping or dual use were tested for association to prospective health-related outcomes, namely change in FEV1 (absolute volume and percent change from baseline), prospective exacerbations, all-cause and respiratory mortality, and incident CVD. FEV₁ changes were computed by subtracting Visit 2 from Visit 3 FEV₁ values and dividing this difference by the number of years between both visits. FEV₁ changes were

calculated as both absolute and relative (as a percentage of the Visit 2 measurement) values. Data
points >5 standard deviations from the mean were excluded from analysis.

The FEV1 outcomes were evaluated using multivariable linear regression models, and the time-to-event outcomes were evaluated using Cox-proportional hazards models using Visit 2 as the starting point. Analyses were adjusted for sex, race, and age at baseline (Visit 2). For time-toevent outcomes baseline FEV1 percentage of predicted was included as a covariate. Since the sample sizes of our vaping/smoking groups were small, these association analyses were performed in all available COPDGene study subjects without stratifying by vaping or smoking exposure. The FDR was controlled at 10% using the Benjamini-Hochberg method.

142

143 Prediction modeling for vaping status and prospective health outcomes

144 Predictive models using only transcript and protein biomarkers were constructed for 145 vaping/smoking groups and prospective health outcomes. For categorical and binary outcomes, 146 linear discriminant analysis (LDA) was used. For change in FEV1 models, elastic net models 147 were constructed. Cross-validation was used to prevent overfitting and estimate predictive 148 performance. Model performance was assessed by cross-validation using the Youden index 149 (sensitivity + specificity - 1), area under the receiver operator characteristic curve (AUROC), and 150 area under the precision recall curve (AUCPR) for binary outcomes. R2 was used to evaluate the 151 performance of change in FEV1 models. Additional details are included in the supplementary 152 materials of the online preprint.

153

154 **Results**

155 Baseline characteristics

156 A visual overview of the study and data flow is included in Supplemental Figures 1 and 157 2. There were 51 and 77 subjects reporting current vaping only or dual use, respectively, at the 158 COPDGene second study visit. Differences in baseline characteristics of these groups along with 159 the current and former cigarette user groups are reported in Table 1. The large majority of 160 subjects in the vaping group (80%) reported vaping at least once a day. The dual user group 161 reported lighter vaping on average, with only 42% reporting daily vaping, and their pack-years 162 exposure to combustible tobacco was similar to the current cigarette user group. FEV1 % of 163 predicted values were comparable for all groups. Biochemical confirmation of nicotine exposure 164 via analysis of plasma cotinine levels in 853 subjects demonstrated elevated cotinine levels in the 165 vaping, dual use, and current cigarette user groups relative to the former cigarette user group 166 (Figure 1, Wilcoxon rank sum test p < 0.005 for all comparisons). A subset of the former cigarette 167 user group had elevated levels of nicotine that could be due to use of nicotine replacement 168 therapy, secondhand exposure to tobacco smoke or e-cigarette aerosols, or unreported smoking 169 or vaping.

170

171 Blood RNA-seq associations with vaping and dual use

A total of 18,303 genes were tested for differential expression analysis of vapers, dual users, and current cigarette users, using former cigarette users as the reference group. The top results from each analysis are shown in Table 2, and complete results are reported in Tables S1-S3. For vapers, three significant associations were identified at an FDR of 10% (Figure 2). Two

of these genes (LINC02470 and NPHP1) were expressed at a higher level in vapers than any of 176 177 the other three groups (p<0.05 for all comparisons, Table S4). The third gene, GPR15, was one 178 of the most well-reported genes upregulated by smoking. This gene was also upregulated in 179 vapers, but to a lesser extent than in either cigarette users or dual users (p < 0.005 for all 180 comparisons). Gene set enrichment analysis identified 16 significant MSigDB Hallmark 181 pathways with the top three processes being related to inflammation, oxidative phosphorylation, 182 and heme metabolism (Table 3). For all significant gene sets, enrichment was in the direction of 183 decreased expression in vapers compared to former cigarette users. Since smoking has been 184 shown to have mixed effects on inflammation, we compared the pattern of gene set enrichment 185 for the Hallmark Inflammation pathway in vapers, current cigarette users, and dual users, and we 186 observed that smoking and dual use show elements of activation and repression of this gene set; 187 the effect of vaping was more clearly downregulation of this pathway (Supplemental Figure 3).

188 For dual users, 90 differentially expressed genes were identified, and 17 of these genes 189 were significant only in the dual user analysis. All 17 genes were also significantly differentially 190 expressed when comparing dual users to current cigarette users, suggesting that these genes have 191 a distinctive response to dual use (p < 0.005 for all comparisons, see Table S5). Gene set 192 enrichment analysis identified four significant Hallmark pathways related to heme metabolism, 193 oxidative phosphorylation, E2F signaling, and interferon gamma response (Table 3). Complete 194 results for the vaping, dual use, and smoking analyses including MSigDB Immunologic 195 Signature pathways are presented in Supplemental Tables S6-S8.

196

197 Proteomic biomarker associations to vaping and dual use

198 A total of 4,979 SOMAscan aptamers mapping to 4,720 unique proteins were tested for 199 association to vaping and smoking groups. The top significantly associated proteins are shown in 200 Table 2 (see Table S9 for complete results), and violin plots for selected top protein biomarkers 201 associated with vaping or dual use are shown in Figure 3. Three protein biomarkers (EDIL3, 202 DPYL5, and KLK13) were significantly associated with vaping status at a 10% FDR, and 203 DPYL5 expression was found to be higher in vapers compared to each of the other groups 204 (p<0.05 for all comparisons, Table S10). One hundred protein biomarkers were associated with 205 dual use, with four (CXA8, Keratin 19, CSKP, and PXDC1) being significantly associated only 206 with dual use. All four of these proteins also showed nominal association (p<0.05) in an analysis 207 comparing dual users to current cigarette users, indicating a distinct response to dual use (Table 208 S11).

209

210 Comparison of biomarker associations to vaping, smoking, and dual use

211 To compare the similarity of the transcriptomic and proteomic responses to each exposure, we 212 constructed pairwise plots of the effect sizes of all significantly associated biomarkers (Figure 4). 213 There was a strong positive correlation between the biomarker responses to smoking and dual 214 use (Pearson's r = 0.76 and 0.88 for RNA and protein, respectively), whereas the vaping 215 biomarker profile had low correlation to the profiles for both dual use and smoking (r between 216 0.23 and 0.44). Certain biomarkers (LINC02470 and DPYL5 protein) had particularly strong and 217 unique associations with vaping. When we compared effect sizes between RNA and proteomic 218 biomarkers associated with vaping and smoking, the correlation was low (r=0.11) as might be 219 expected given various potential sources of origin for circulating blood proteins.

220

221 Classification accuracy for vaping/smoking behavior using biomarker panels

222 To determine how well RNA and protein biomarkers could classify subjects according to 223 their vaping/smoking behavior, we used a nested cross-validation approach to provide an 224 unbiased estimate of the classification performance achievable by multi-class prediction models 225 using linear discriminant analysis (LDA). The performance of this model is shown in Table 4, 226 where for each group the task was to distinguish that group from all other groups combined. The 227 model achieved good discrimination for current cigarette users (Youden index (YI) = 0.81) and 228 former cigarette users (YI = 0.80) and had statistically significant but less accurate performance 229 for vapers (YI = 0.53) and dual users (YI = 0.55). More detailed metrics for each pairwise 230 contrast (Table S12) demonstrates that the models do better in discriminating vapers from 231 current cigarette users than former cigarette users (YI = 0.73 and 0.50, respectively), whereas for 232 dual users, model discrimination was better for former cigarette users (YI = 0.82) than current 233 cigarette users (YI = 0.34), providing further evidence of the similarity between dual use and 234 current smoking biomarker profiles.

235

236 Vaping and dual use biomarkers and longitudinal outcomes

To determine whether biomarkers of vaping or dual use were associated with prospective health-related outcomes, we tested the 92 RNA transcripts and 101 protein biomarkers associated with vaping and/or dual use for association to multiple health outcomes in all COPDGene subjects. Twenty-one transcripts and 88 protein biomarkers were associated with one or more of the studied outcomes at a 10% FDR level. Of the vaping-associated biomarkers, two (KLK13

and DPYL5) were associated with loss of FEV1, and KLK13 was also associated with mortality.
Boxplots for the top four vaping or dual use proteins associated with all-cause mortality are
shown in Figure 5, and all significant biomarker associations are shown in Tables S13-S16.

We then determined whether the effect of vaping or dual use on each protein biomarker was consistent with higher or lower risk for each adverse health outcome, and we observed that the direction of the exposure effect was overwhelmingly towards increased risk for adverse health events (Figure 6). Out of 246 total significant associations to health outcomes, 224 (91%) showed concordance between the effect of vaping or dual use and the direction of association to increased risk. Both of the vaping-associated biomarkers (KLK13 and DPYL5) showed concordant effects for higher health risk.

To estimate the accuracy of multi-marker panels of vaping and dual use biomarkers for predicting prospective health outcomes, we constructed predictive models for FEV1 decline, allcause mortality, COPD exacerbations, and incident CVD using only the vaping or dual useassociated RNA and protein biomarkers. Models using the seven vaping-associated biomarkers alone gave non-informative predictions, but models using the 190 dual use-associated biomarkers gave informative predictions with moderate accuracy for FEV1 decline, all-cause mortality and respiratory exacerbations (Table 5).

259

260 *Replication of previously reported vaping biomarker associations*

A recently published review of vaping biomarkers listed 14 inflammatory and matrix degradation protein biomarkers that had been previously associated with vaping[19]. We examined the results from these 14 biomarkers at the RNA and protein level for association to

vaping or dual use, and we observed associations at nominal significance (p<0.05) for four
biomarkers (*IL1B*, ICAM1 [both RNA and protein], IL-6, and MMP9, see Table S17).

266

267 Discussion

268 Identifying validated biomarkers of vaping and dual use is an important tool both for 269 guiding ENDS users as to the risks of these devices and effective regulation of ENDS. This study 270 of established adult cigarette users identified significant associations of six and 190 blood 271 molecular markers with vaping and dual use, respectively. Because of the comprehensive nature 272 of the 'omics measurements, we were able to compare overall molecular profiles of vaping, dual 273 use, and smoking. These analyses found that the vaping profile was substantially different from 274 current smoking, whereas dual use and smoking were similar but not identical. Biomarkers 275 associated with vaping and dual use were also associated with multiple cardiopulmonary health 276 outcomes, and reasonably predictive accuracy for some of these outcomes could be achieved for 277 models using dual use biomarkers.

278 A previous metabolomic biomarker study by Goniewicz et al. demonstrated that vaping 279 is associated with metabolomic changes, albeit at generally lower levels compared to current 280 cigarette users or dual users[20]. A recent study of vapers versus non-cigarette users identified 281 numerous changes in plasma biomarkers associated with inflammation, oxidative stress, and 282 extracellular matrix degradation[19]. A recent meta-analysis of biomarkers of ENDS versus 283 cigarettes reported a more favorable biomarker profile of ENDS use, though the last author of the 284 study has been reported to have ties to the tobacco industry[21,22]. Another systematic review 285 also reported reduced levels of some biomarkers in ENDS users relative to current cigarette

users, but this is not consistent for all biomarkers (Hiler et al., 2021). By examining the 286 287 correlation in biomarker profiles for vaping, dual use, and smoking, we observed that the vaping 288 profile is largely distinct from both the dual use and smoking profile which are in turn highly 289 correlated to each other. We did however observe multiple examples of shared RNA and protein 290 biomarkers between smoking, vaping, and dual use, such as GPR15, a regulator of inflammation 291 and T-cell trafficking. We also provided independent validation for previously reported vaping 292 or dual use associations with IL1B, ICAM1, IL-6, and MMP9, all of which are known to 293 influence inflammation (IL-1B can induce MMP-9 expression and activity).

294 Both vaping and dual use are associated with diverse effects on biological pathways 295 related to aspects of inflammation, oxidative phosphorylation, and coagulation-related pathways. 296 Previous studies have also shown that long non-coding RNAs (lncRNAs) are associated with 297 vaping[23,24], and in our work we identified LINC02470 as a novel vaping biomarker. 298 LINC02470 has previously been reported to modulate Wnt-beta catenin signaling via exosomal 299 secretion from bladder cancer cells[25]. Because Tang et al. previously demonstrated bladder 300 urothelial hyperplasia in mice exposed daily to e-cigarette aerosols, the finding of LINC02470 in 301 the circulation of human ENDS users is highly concerning. We also identified DPYL5 as being 302 uniquely upregulated in vaping subjects. DPYL5 is primarily expressed in brain tissue and glial 303 cells, though it is also expressed at detectable levels in the gastrointestinal (GI) tract. DPYL5 is 304 potentially an important vaping biomarker, because it was also predictive of future loss of lung 305 function. To our knowledge, this is the first report of DPYL5 as a specific and clinically relevant 306 biomarker of vaping, a finding that requires further independent validation.

307 Many of the biomarkers altered by vaping and dual use are also associated with risk of 308 adverse health events such as loss of lung function, respiratory exacerbations, and mortality. For

309 the overwhelming majority of biomarkers, the direction of effect of vaping and dual use was 310 consistent with increased health risk. This extends numerous prior observations linking vaping to 311 a variety of pulmonary symptoms and alterations of cardiovascular physiology[26], providing an 312 important link to longer-term health outcomes and suggesting that some of these biomarkers may 313 be useful in assessing health risks of specific vaping devices and e-liquid formulations. For dual 314 use, a multi-marker panel of associated biomarkers achieved modest predictive accuracy for 315 some important outcomes. For vapers, the biomarker profile was more subtle, and with our 316 current sample size we did not identify a sufficient number of biomarkers to enable accurate 317 multi-marker prediction of health outcomes.

318 The strengths of this study are the high-throughput approach to biomarker discovery, the 319 characterization of associations to prospective health events, and the use of machine learning to 320 assess the predictive performance of multimarker panels. Limitations include a modest sample 321 size of vapers and dual users and the lack of independent replication due to lack of available 322 cohorts with similar biomarker data and exposure characterization. Information regarding 323 specific vaping devices and fluids was limited and reflects the challenges posed by the rapid 324 evolution of vaping devices over the study period. Our findings cannot be assumed to generalize 325 to newer-generation vaping devices which will require dedicated study, and our findings in 326 adults do not necessarily apply to other important groups such as adolescents.

In conclusion, this study identified over one-hundred transcriptomic and proteomic biomarkers associated with vaping and dual use, and many of these biomarkers are also associated with prospective cardiopulmonary health outcomes. Prediction of health outcomes using multimarker panels can provide informative prediction with room for improvement, and validation in independent cohorts will increase confidence in individual biomarkers and multi-

- 332 marker models. Larger-scale studies with greater power would be likely to identify additional
- 333 biomarkers that could further improve predictive model performance.
- 334

335 Data availability

- 336 Supplemental materials are included in the medRxiv online preprint (doi:
 337 https://doi.org/10.1101/2022.09.19.22280093).
- 338 Underlying data
- 339 <u>NCBI</u> dbGAP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi340 bin/study.cgi?study_id=phs000179.v6.p2
- 341
- 342

343 **Competing interests**

344 EKS and PJC have received grant support from GlaxoSmithKline and Bayer. JY has received 345 institutional grant support from Bayer and personal fees from Bride Biotherapeutics outside the

submitted work.

347

348 **Grant information**

This work was supported by NHLBI K08HL141601, K08HL146972, K01HL157613,
R01HL124233, U01 HL089897, R01 HL147326, and U01 HL089856. The COPDGene study

- 351 (NCT00608764) is also supported by the COPD Foundation through contributions made to an
- 352 Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals,
- 353 Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.

Table 1 Bas	eline characteristic	s of the vaning a	and smoking group	S
Table L. Das		s of the vaping a	und smoking group	0

	Current cigarette users (n = 1.328)	Former cigarette users (n = 2.436)	Vapers (n = 51)	Dual users (n = 77)	P- value
Age	59.6 (9.5)	68.6 (11.9)	64.6 (10.2)	61.6 (9.9)	< 0.001
Sex, % male	50.5%	52.0%	39.2%	48.1%	0.3
% Non-Hispanic Whites	47.1%	82.4%	88.2%	71.4%	< 0.001
BMI	27.2 (8.4)	28.7 (7.6)	29.2 (9.6)	26.9 (7.1)	< 0.001
Smoking pack-years	41.1 (25.8)	38.0 (29.2)	50.1 (26.3)	45.0 (26.3)	< 0.001
FEV ₁ (L)	2.2 (1.1)	2.1 (1.2)	2.1 (1.2)	2.1 (1.2)	< 0.001
FEV ₁ , % predicted	81.9 (28.0)	82.0 (35.6)	83.2 (32.7)	76.9 (29.7)	0.2
FVC (L)	3.1 (1.4)	3.0 (1.4)	3.1 (1.5)	3.0 (1.5)	0.02
Use of e-cigarettes:					
Less than once a month	NA	NA	0.0%	2.6%	0.3
Less than once a week	NA	NA	0.0%	15.6%	0.003
Some days (1-3 days a week)	NA	NA	4.0%	27.3%	< 0.001
Most days	NA	NA	16.0%	13.0%	0.6
Every day	NA	NA	80.0%	41.6%	< 0.001
Cartridge size:					
0 mg	NA	NA	8.2%	4.0%	0.3
6-8 mg	NA	NA	20.4%	16.0%	0.5
9-12 mg	NA	NA	14.3%	9.3%	0.4
13-16 mg	NA	NA	14.3%	6.7%	0.2
Do not know	NA	NA	22.5%	52.0%	0.001
Uther		NA	20.4%	12.0%	0.2
Number of e-cigarettes used (last 24 hours)	NA	NA	10 (16)	3 (10)	< 0.001
Number of cartridges used/week	NA	NA	2 (6)	1 (1)	0.002
E-cigarette brand:					
Blu	NA	NA	4.6%	17.4%	0.04
Henley	NA	NA	2.3%	1.5%	0.7
Joye	NA	NA	0.0%	2.9%	0.3
NJOY	NA	NA	2.3%	8.7%	0.2
V2	NA	NA	2.3%	2.9%	0.8
Other	NA	NA	90.9%	71.0%	0.01
SGRQ Symptom Score	28.7 (40.4)	17.9 (39.0)	15.8 (46.3)	43.5 (48.5)	< 0.001
Respiratory exacerbation	14.4%	17.9%	21.6%	23.4%	0.01
CVD	18.5%	25.8%	15.7%	18.2%	< 0.001

Continuous variables are reported as medians (interquartile ranges). Categorical variables are reported as percentages. Kruskal-Wallis rank sum tests were used for continuous variables. Chi-square tests were used for categorical variables. BMI: Body mass index; CVD: Cardiovascular disease (history of stroke, heart attack, coronary artery disease, coronary artery bypass graft surgery, peripheral artery disease, and/or cardiac angina); Respiratory exacerbation: At least one respiratory exacerbation (acute worsening of respiratory symptoms that required systemic steroids and/or antibiotics) in the previous year; FEV₁: Forced expiratory volume in 1 second; FEV₁, % predicted: Observed FEV1 / Predicted FEV1 based Hankinson reference equation; FVC: Forced vital capacity; SGRQ: St. George's respiratory questionnaire score. % LAA-950: Percentage of CT low attenuation less than -950 HU at end-inspiration using Thirona software; % Segmental airway wall thickness: Percentage of the wall relative to the total bronchial area for the segmental airways. NA = Not applicable. Table 2. Top 5 differentially associated genes and proteins for vapers, dual users, and current cigarette users.

	Genes							
	Gene	Ensembl gene ID	Log fold change	q-value	Protein	Uniprot ID	Mean difference	q- value
Vaping	GPR15	ENSG00000154165	0.90	< 0.001	EDIL3	043854	0.52	0.03
1 0	NPHP1*	ENSG00000144061	0.79	0.05	DPYL5*	Q9BPU6	0.62	0.03
	LINC02470*	ENSG00000225231	1.37	0.07	Kallikrein 13	Q9UKR3	0.54	0.09
Dual use					Placental alkaline			de a
	SEMA6B	ENSG00000167680	2.10	< 0.001	phosphatase	P05187	1.12	<0.00 al a
	MIR124-1HG	ENSG00000253230	2.32	< 0.001	PPBN	P10696	0.92	<0.00
	GPR15	ENSG00000154165	1.71	< 0.001	LPLC1	Q8TDL5	0.88	<0.00
	LRRN3	ENSG00000173114	1.59	< 0.001	PSP-94	P08118	0.88	<0.00
	CTTNBP2	ENSG0000077063	1.52	< 0.001	sICAM-5	Q9UMF0	0.84	<0.00
Current					Placental alkaline			BY-N
cigarette	GPR15	ENSG00000154165	1.34	< 0.001	phosphatase	P05187	1.00	<0.00 ⁴
use	MIR124-1HG	ENSG00000253230	1.79	< 0.001	PPBN	P10696	0.89	<0.00
	SEMA6B	ENSG00000167680	1.51	< 0.001	PSP-94	P08118	0.77	<0.00
	LRRN3	ENSG00000173114	1.21	< 0.001	LPLC1	Q8TDL5	0.72	<0.00
	P2RY6	ENSG00000171631	0.88	< 0.001	PIGR	P01833	0.73	<0.00

P2RY6ENSG000001716310.88<0.001</th>PIGRP018330.73<0.001</th>PigrDifferential gene expression and protein association analyses was performed for each vaping/smoking group using the former cigarette user group
as reference and adjusting for age, sex, race and batch effects. Up to 5 significant biomarkers are shown. "Uniquely" significant biomarkers (i.e.
biomarkers significant at 10% FDR for one contrast but not for any of the other contrasts) are indicated with *. Effect sizes are reported as log fold
change for the RNA-seq analysis and mean difference in normalized RFU (relative fluorescence units) for the proteomics analysis. Q-values
calculated using the Benjamini-Hochberg procedure implemented in the p.adjust function in R.P018330.73<0.001</td>Pigr23

Table 3. Top 5 significant (adjusted P-values < 0.1) MSigDB Hallmark pathways from

		Pathway ID	Number of		
	MSigDB Hallmark pathway		genes	NES	Adjusted P-valu
Vaping	Inflammatory Response	M5932	163	-4.10	6.3x10 ⁻¹⁰
	Oxidative Phosphorylation	M5936	200	-4.01	2.8x10 ⁻⁹
	Heme Metabolism	M5945	195	-3.82	2.7x10 ⁻⁸
	TNF-α Signaling via NF-kB	M5890	179	-3.85	3.7x10 ⁻⁸
	Complement	M5921	171	-3.50	4.0x10 ⁻⁷
Dual Use	Heme Metabolism	M5945	195	-5.53	3.9x10 ⁻¹⁷
	Oxidative Phosphorylation	M5936	200	-3.70	1.7x10 ⁻⁷
	E2F Targets	M5925	199	-3.69	2.0x10 ⁻⁷
	Interferon gamma response	M5913	194	-2.90	1.4x10 ⁻⁴
Current	Heme Metabolism	M5945	195	-8.68	1.2x10 ⁻⁴⁸
cigarette	MYC Targets V1	M5926	200	3.33	6.1x10 ⁻⁶
use	Estrogen Response Late	M5907	145	-2.89	2.2x10 ⁻⁴
	Xenobiotic Metabolism	M5934	151	-2.86	3.2x10 ⁻⁴

differential gene expression analyses for the vaping and smoking groups.

Epithelial mesenchymal

transition

Gene set enrichment analysis (GSEA) was performed using the results from the differential expression analysis comparing vapers, dual users, or current cigarette users to former cigarette users. Genes were ranked for enrichment analysis by log fold change. The top 5 results from the MSigDB Hallmarks gene sets are shown ordered by p-value. The "number of genes" column is the number of genes associated with the GSEA pathway tha could be mapped to the differential expression results. Abbreviations: NES = normalized enrichment score. UV= ultraviolet light.

129

-2.86

M5930

3 8x10⁴

	Integrated RNA-seq and proteomic data				
	Current	Former cigarette	Vapers	Dual users	
	cigarette users	users			
AUROC	0.94	0.94	0.71	0.71	
AUPRC	0.85	0.97	0.06	0.04	
Youden index	0.81	0.80	0.53	0.55	

Table 4. Multi-class prediction of vaping and smoking groups using multi-omic biomarkers

Linear discrimination analysis models were used to classify vaping and smoking groups. For each group, LDA models are constructed to distinguish that group from the other three using 10-fold nested cross validation (CV) to estimate performance. Abbreviations: AUROC = Area under the receiving operating characteristic curve; AUPRC = Area under the precision-recall curve. The Youden Index (YI) metric was used to summarize the model performance at the optimal cutoff on the area under the receiver operating curve.

1

Table 5. Performance metrics of prediction models for prospective health outcomes.

					Youden			
Biomarker Panel	Outcome	Sample size (events)	AUROC	AUPR	Index	R2		
	Δ FEV1 (ml/yr)	642	NA	NA	NA	0.08		
	Δ FEV1 (% of baseline)	642	NA	NA	NA	0.17		
Dual Use Biomarkers	Overall mortality	2388 (246)	0.68	0.38	0.36	NA		
	Exacerbation >= 1	2231 (811)	0.63	0.51	0.25	NA		
	Incident CVD	1700 (183)	0.68	0.34	0.36	NA		

Prediction models for the indicated outcomes were constructed using elastic net for change in FEV1 models and linear discriminant analysis for binary outcomes. Δ FEV1 (ml/yr) = (FEV1 at visit 3 - FEV1 at visit 2) / years between visits. Δ FEV1 (% of baseline) = Δ FEV1 (ml/yr) / FEV1 at visit 2. Exacerbation = 1 if subjects reported one of more exacerbation over the follow-up period after visit 2 and 0 otherwise. Incident CVD = 1 if subject reported new diagnosis of CVD after visit 2, and subjects with existing CVD at visit 2 were excluded. AUROC = area under the receiver operator characteristic. AUPR = area under the precision-recall curve. R2 = r-squared.

Figure Legends:

Figure 1. Plasma cotinine levels by vaping/smoking group. In a subset of subjects, plasma metabolomics data was measured using the Metabolon Global Metabolomics Platform. Violin plots of log-transformed cotinine raw area counts are shown. Cotinine levels are significantly higher in all three groups relative to FS (Wilcoxon rank sum p < 0.005 for all three comparisons). FS = former cigarette users. CS = current cigarette users.

Figure 2. Significantly associated vaping RNA biomarkers. Three RNA biomarkers were significantly associated at 10% FDR in the analysis comparing vapers to former cigarette users. *NPHP1* and *LINC02470* were significantly associated in the vaping but not the smoking or dual use comparison to former cigarette users. *GPR15* is significantly elevated in all three groups relative to former cigarette users, but its expression is relatively lower in vapers relative to dual users and current cigarette users (p<0.005 for all comparisons).

Figure 3. Top protein biomarkers significantly associated with vaping or dual use. The distribution of the top significantly associated protein biomarkers in the analysis of vapers or dual users versus former cigarette users. DPYL5 is significantly elevated in vapers relative to all other vaping/smoking groups (p<0.005). KLK13 is significantly associated with vapers, dual users, and current cigarette users when compared to former cigarette users. s-ICAM5 and Secretoglobin family member 3A member 1 were significantly associated with dual users and current cigarette users when compared to former cigarette users.

Figure 4. Correlation of biomarker responses between vapers, dual users, and current cigarette users. Comparison of the biomarker association profiles demonstrates that while the dual user and current cigarette user profiles are very similar, the vaping biomarker profile is more distinct. For the RNA and protein biomarker analysis of vaping/smoking groups versus former cigarette users, the effect sizes for each pair of comparisons were plotted and the Pearson correlation of effect sizes was calculated. In each pairwise comparison, only biomarkers significant in at least one of analyses were analyzed. In row A, vaping-associated RNA biomarker effects are compared to current cigarette user effects (left), dual user effects (middle), and then dual user and current cigarette user effects are compared (right). In row B, the corresponding protein biomarker effects are compared.

Figure 5. Top protein vaping and dual use biomarkers significantly associated with overall mortality. The dual use-associated proteins Growth hormone receptor, MIC-1, and HE4 were significantly associated with overall mortality. KLK-13 was the only vaping associated biomarker that was also associated mortality. All associations were significant at a false discovery rate of 10%.

Figure 6. Concordance analysis of biomarker associations to vaping/dual use and adverse health outcomes. For protein biomarkers that were significantly associated with at least one health outcome and vaping (n=2) or dual use (n=86), we plotted the effect of the exposure (vaping or dual use) against the effect with respect to the health outcome. Since some biomarkers were significantly associated with multiple health outcomes, the total number of analyzed

associations was 246. The top panel shows the relationship between exposure effect and change FEV1 (ml/yr) where each of the 107 associations was concordant for loss of FEV1. Change in FEV1 is calculated as visit 3 value - visit 2 value, meaning negative values indicate loss of lung function. The bottom panel shows the relationship between exposure effect and hazard ratio for all cause mortality, respiratory mortality, exacerbations, or incident cardiovascular disease. 117 of 139 associations were concordant for higher health risk. Exposure effect is the beta coefficient from the dual use versus former cigarette users analysis, except for DPYL5 and KLK13 which is from the vapers versus former cigarette users analysis.

References

- <u>1</u> Gentzke AS, Wang TW, Jamal A, *et al.* Tobacco Product Use Among Middle and High School Students United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:1881–8.
- 2 Mayer M, Reyes-Guzman C, Grana R, *et al.* Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults. *JAMA Netw Open* 2020;**3**:e2020694.
- <u>3</u> Li D, Sundar IK, McIntosh S, *et al.* Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. Tobacco Control. 2019;:tobaccocontrol – 2018. doi:10.1136/tobaccocontrol-2018-054694
- <u>4</u> Yao T, Max W, Sung H-Y, *et al.* Relationship between spending on electronic cigarettes, 30-day use, and disease symptoms among current adult cigarette smokers in the U.S. *PLoS One* 2017;**12**:e0187399.
- 5 St Helen G, Eaton DL. Public Health Consequences of e-Cigarette Use. *JAMA Intern Med* 2018;**178**:984–6.
- <u>6</u> Smith ML, Gotway MB, Crotty Alexander LE, *et al.* Vaping-related lung injury. *Virchows Arch* 2021;**478**:81–8.
- 7 Cherian SV, Kumar A, Estrada-Y-Martin RM. E-Cigarette or Vaping Product-Associated Lung Injury: A Review. *Am J Med* 2020;**133**:657–63.
- <u>8</u> Hammond D, Reid JL, Rynard VL, *et al.* Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ* 2019;**365**:12219.
- 9 Miech R, Johnston L, O'Malley PM, *et al.* Trends in Adolescent Vaping, 2017–2019. *N* Engl J Med 2019;**381**:1490–1.
- 10 Miech R, Johnston L, O'Malley PM, *et al.* Adolescent vaping and nicotine use in 2017-2018 U.s. national estimates. *N Engl J Med* 2019;**380**:192–3.
- <u>11</u> Aronson JK. Research priorities in biomarkers and surrogate end-points. *Br J Clin Pharmacol* 2012;**73**:900–7.
- <u>12</u> FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and Other Tools) Resource*. Food and Drug Administration (US) 2016.
- <u>13</u> Regan EA, Hokanson JE, Murphy JR, *et al.* Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010;**7**:32–43.

- <u>14</u> Gold L, Ayers D, Bertino J, *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* 2010;**5**:e15004.
- <u>15</u> Gillenwater LA, Kechris KJ, Pratte KA, *et al.* Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema. *Metabolites* 2021;**11**. doi:10.3390/metabol1030161
- <u>16</u> Ritchie ME, Phipson B, Wu D, *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;**43**:e47.
- <u>17</u> Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc* 1995;**57**:289–300.
- <u>18</u> Gennady Korotkevich, Vladimir Sukhov, Nikolay Budin, Boris Shpak, Maxim N. Artyomov, Alexey Sergushichev. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. biorxiv. 2021. doi:10.1101/060012
- <u>19</u> Singh KP, Lawyer G, Muthumalage T, *et al.* Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. *ERJ Open Res* 2019;**5**. doi:10.1183/23120541.00182-2019
- 20 Goniewicz ML, Smith DM, Edwards KC, *et al.* Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. *JAMA Netw Open* 2018;**1**:e185937.
- 21 Akiyama Y, Sherwood N. Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicology Reports. 2021;8:282–94. doi:10.1016/j.toxrep.2021.01.014
- 22 Neil Sherwood. TobaccoTactics. 2020.https://tobaccotactics.org/wiki/neil-sherwood/ (accessed 26 Jun 2022).
- 23 Tommasi S, Caliri AW, Caceres A, *et al.* Deregulation of Biologically Significant Genes and Associated Molecular Pathways in the Oral Epithelium of Electronic Cigarette Users. *Int J Mol Sci* 2019;**20**. doi:10.3390/ijms20030738
- 24 Kaur G, Singh K, Maremanda KP, *et al.* Differential plasma exosomal long non-coding RNAs expression profiles and their emerging role in E-cigarette users, cigarette, waterpipe, and dual smokers. *PLoS One* 2020;**15**:e0243065.
- 25 Huang C-S, Ho J-Y, Chiang J-H, *et al.* Exosome-Derived LINC00960 and LINC02470 Promote the Epithelial-Mesenchymal Transition and Aggressiveness of Bladder Cancer Cells. *Cells* 2020;**9**. doi:10.3390/cells9061419
- <u>26</u> Bozier J, Chivers EK, Chapman DG, *et al.* The Evolving Landscape of e-Cigarettes: A Systematic Review of Recent Evidence. *Chest* 2020;**157**:1362–90.